I predict a serious influx of SE Asian interest in CYDY. Leronlimab is a very recent addition to their knowledge base. Before April, leronlimab was largely unknown except to a few in the medical/research field. I doubt we had many ( if any) investors from that region. Now events are evolving in such a way that leronlimab could end up better known in that region than our own.
I don't think Lucio Tan, former president Estrada, and the other "in-crowd" that got themselves on the CSP list would overlook such a juicy opportunity and (thanks to the fud) a very reasonable share price. Buying into a biotech with Cytodyn's prospects is a no-brainer. Yes, conjecture and appreciation that these people didn't get where they are by being stupid.
Cytodyn isn't just sending them a drug, it's also giving them ideas! If the US/BP is too stupid to welcome Cytodyn into its fold (where there could be some cooperation), then there are other options.
Leronlimab has immense therapeutic and strategic value. The owners of this drug and, in fact, it's headquarters and operations could be centered elsewhere. ( pure conjecture but not illogical).
Our total capitalization is cheap compared to Leronlimab's promise.
The USA better grasp what they have or risk losing it. Further, BP better read the tea leaves >> either learn to accept and cooperate or risk leronlimab being controlled from elsewhere with serious vicious consequences to their revenue streams.
News 
Market Data 
Discover 
